Prostate cancer treatment patterns among racial/ethnic groups in Florida

Journal of the National Medical Association

Volumn 101, Issue 9, 2009, Pages 936-943

  Xiao, Hong ^a,d   Warrick, Cynthia ^b   Huang, Youjie ^c  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b ELIZABETH CITY STATE UNIVERSITY   (United States)

^c FLORIDA DEPARTMENT OF HEALTH   (United States)

^d Dyson Pharmacy Bldg ^*  (United States)

Author keywords

Health disparities; Prostate cancer; Race ethnicity

Indexed keywords

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGISTRY; CONTROLLED STUDY; DEMOGRAPHY; ETHNIC DIFFERENCE; ETHNICITY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RACE DIFFERENCE; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 70350074962     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)31042-7     Document Type: Article

References (50)

1. Morbidity and Mortality Weekly Report, Prostate cancer awareness month. 2000.
2. American Cancer Society. Cancer Facts & Figures, 2008.
3. Edwards BK, Brown ML, Wingo PA, et al. Annual Report to the Nation on the Status of Cancer, 1975-2002, Featuring Population-Based Trends in Cancer Treatment. J Natl Cancer Inst. 2005;97(19):1407-1427
4. American Cancer Society. Cancer Facts and Figures for African American 2007-2008.
5. Eastham JA, Kattan MW. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol. 2000;163:143-145.
6. Powell IJ, Banerjee M, Novall M, et al. Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease. Urology. 2000;55:246-251. (Pubitemid 30069925)
7. Freeland SJ, Jalkut M, Dorey F, et al. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology. 2000;56:87-91. (Pubitemid 30408660)
8. Tarman GJ, Kane CJ, Moul JW, et al. Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. Urology. 2000;56:1016-1020.
9. Zhang W, Sesterhenn IA, Connelly RR, et al. Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. J Urol. 2000;163:131-136.
10. Freedland SJ, Sutter ME, Naitoh J, Dorey F, Csathy GS, Aronson WJ. Clinical characteristics in Black and White men with prostate cancer in an equal access medical center. Urology. 2000; 55(3): 387-390. (Pubitemid 30110590)
11. Sartor O, Zheng Q, Eastham JA. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology. 1999;53:378-380. (Pubitemid 29063330)
12. Kubricht WS, Williams BJ, Whatley T, et al. Serum testosterone levels in African-American and white men undergoing prostate biopsy. Urology. 1999;54:1035-1038.
13. Freeland SJ, Dorey F, Aronson WJ. Multivariate analysis of race and adverse pathologic findings after radical prostatectomy. Urology. 2000;56:807-811. (Pubitemid 30799246)
14. Shekarriz B, Tiguret R, Upadhyay J, et al. Impact of location and multifocality of positive surgical margins on disease-free survival following radical prostatectomy: A comparison between African-American and white men. Urology. 2000; 55:899-903. (Pubitemid 30330796)
15. Merill R. Demographics and health-related factors of men receiving prostate-specific antigen screening in Utah. Prev Med. 2001;33:646-652.
16. Liu L, Cozen W, Bernstein L, et al. Changing relationship between socioeconomic status and prostate cancer incidence. J Natl Cancer Inst. 2001;93(9):705-709. (Pubitemid 32492812)
17. Tarone R, Chu K, Brawley O. Implications of stage-specific survival rates in assessing recent declines in prostate cancer morality rated. Epidemiology. 2000;11(2):167-170. (Pubitemid 30112017)
18. Smith R, Cokkinides V, von Eschenbach A, et al. American cancer society guidelines for the early detection of cancer. CA Cancer J Clin. 2002;25(1):8-22. (Pubitemid 34110468)
19. United States Preventive Services Task Force. Screening for prostate cancer: Recommendation and rationale. Ann Intern Med. 2002;137:915-916.
20. Cooper C, Merritt T, Ross L, et al. To screen or not to screen, when clinical guidelines disagree: Primary care physicians' use of the PSA test. Prev Med. 2004;38(2):182-191. (Pubitemid 38050289)
21. Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol. 2004;71:29-33. (Pubitemid 38452899)
22. Denmeade SR, Isaacs JT. Development of prostate cancer treatment: the good news. Prostate. 2004;58:211-224. (Pubitemid 38168917)
23. Crook J, Lukka H, Klotz L, et al. Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. CMAJ. 2001;164(7):975-981. (Pubitemid 34412225)
24. Morton GC. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol. 2005;17:219-227. (Pubitemid 40716444)
25. Potters L. Permanent prostate brachytherapy in men with clinically localized prostate cancer. Clin Oncol. 2003;15:301-315. (Pubitemid 37069640)
26. Arterbery VE, Frazier A, Dalmia P, et al. Quality of life after permanent prostate implant. Semin Surg Oncol. 1997;13:461-464. (Pubitemid 27469231)
27. Potters L, Cao Y, Calugaru E, et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001;50:605-614 (Pubitemid 32519593)
28. Brandeis JM, Litwin MS, Burnison CM, et al. Quality of life outcomes after bracytherapy for early stage prostate cancer. J Urol. 2000;163:851-857 (Pubitemid 30091630)
29. Denis LJ. The role of active treatment in early prostate cancer. Radiother Oncol. 2000;57:251-258. (Pubitemid 30943104)
30. Smedley BD, Stith AY, Nelson AR, Editors. Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Institute of Medicine. Washington, DC: National Academies Press; 2003.
31. Kressin NR, Petersen LA. Racial differences in the use of invasive cardiovascular procedures: review of the literature and prescription for future research. Ann Intern Med. 2001;135:352-366.
32. Young CJ, Gaston RS. Medical Progress: Renal Transplantation in Black Americans. N Engl J Med. 2000;343(21):1545-1552.
33. Xiao H, Campbell C, Song K. "A Trend Analysis of Organ Transplantation Among Racial or Ethnic Groups." J Natl Med Assoc. 2002;94(1):15-20.
34. Randall TC and Armstrong K. Differences in Treatment and Outcome Between African-American and White Women With Endometrial Cancer. J Clin Oncol. 2003;21(22):4200-4206. (Pubitemid 46606189)
35. Katz JN. Patient Preferences and Health Disparities. JAMA. 2001;286(12):1506-1509
36. Epstein AM, Ayanian JZ. Racial Disparities in Medical Care. N Engl J Med. 2001;344(19):1471-1473
37. Yancy CW, Fowler MB, Colucci WS, et al. Race and the Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure. N Engl J Med. 2001;344(18):1358-1365 (Pubitemid 32378390)
38. Jha AK, Shlipak MG, Hosmer W, et al. Racial Differences in Mortality Among Men Hospitalized in the Veterans Affairs Health Care System. JAMA. 2001;285(3):297-303. (Pubitemid 32095032)
39. SPSS Inc. 1999. SPSS Base 11.0 for Windows User's Guide. Chicago, IL: SPSS Inc.
40. Xiao H, Gwede C, Kiros G, Milla K. Analysis of Prostate Cancer Incidence Using Geographic Information System and Multilevel Modeling. J Natl Med Assoc 2007;99(3):218-225. (Pubitemid 46399379)
41. Johns BA, Liu W, Araujo AB, et al. Explaining the Race Difference in Prostate Cancer Stage at Diagnosis. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2825-2834.
42. Oakley-Girvan I, Kolonel LN, Gallagher RP, et al. Stage at Diagnosis and Survival in a Multiethnic Cohort of Prostate Cancer Patients. Am J Public Health. 2003;93(10): 1753-1759. (Pubitemid 38477646)
43. Aus G, Abbou C, Bolla M. et al. EAU Guidelines on Prostate Cancer Eur Urol. 2005;48(4):546-551.
44. Zhou EH, Ellis RJ, Cherullo E, et al. Radiotherapy and Survival in Prostate Cancer Patients: A Population-Based Study. Int J Radiat Oncol Biol Phys. 2008;(In Press, Corrected Proof). Assessed October 3, 2008.
45. Bill-Axelson A, Holmberg L, Filen F, et al. Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. J Natl Cancer Inst. 2008;100(16):1144-1154.
46. Bill-Axelson A, Holmberg L, Ruutu M ,et al. Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. N Engl J Med. 2005;352(19):1977-1984.
47. Holmberg L, Bill-Axelson A. A Randomized Trial Comparing Radical Prostatectomy with Watchful Waiting in Early Prostate Cancer. N Engl J Med. 2002;347(11):1977-1984. (Pubitemid 34988336)
48. Wong Y, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296:2683-3269 (Pubitemid 44917546)
49. Silcocks, PB. Watchfulness may not be as good as surgery for prostate cancer. BMJ. 2002;325:1423.
50. Ferrer M, Siarez KF, Giedea F, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(2):421-432.